Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRPP Therapy in Recurrent Glioblastoma Multiforme
NCT05589961Phase 1Unknown
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Oct 2022
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab and pirfenidone in glioblastoma multiforme (GBM), sponsored by The Second Hospital of Hebei Medical University. Status: unknown.
02
Drugs
pembrolizumabpirfenidone
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05589961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05589961.